TRIM28 drives immune evasion via PARP1 SUMOylation and NAD + depletion in clear cell renal cell carcinoma
Journal for ImmunoTherapy of Cancer · 2025-10 · 13 (10) · e013025
DOI: 10.1136/jitc-2025-013025 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 23.10.2025. Verfasst von Xiangpeng Zhan und 10 weiteren Autor:innen. Beteiligte Einrichtung: Jiangxi Provincial Key Laboratory of Urinary System Diseases, Department of Urology, the First Affiliated Hospital, Jiangxi Medical College, Nanchang…. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Tripartite Motif-Containing Protein 28, Poly (ADP-Ribose) Polymerase-1, Kidney Neoplasms. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Jiangxi Provincial Health Commission Technology Creative Key Project, Medical Interdisciplinary Innovation Fund of Nanchang University, Jiangxi Provincial Natural Science Foundation for Distinguished Young Scholars.
Abstract (Originalsprache)
Background
Immune checkpoint blockade (ICB) therapy has demonstrated significant clinical potential in a variety of cancers; however, its efficacy in clear cell renal cell carcinoma (ccRCC) remains suboptimal. In ccRCC, an increased infiltration of CD8 + T cells does not necessarily correlate with improved prognosis, indicating the presence of unique immune evasion mechanisms within the tumor microenvironment (TME).
Methods
Tripartite motif-containing 28 (TRIM28) was identified as a potential therapeutic target through single-cell transcriptomics (GSE159115) and Geneformer-based perturbation screening. Functional validation was performed by constructing shTRIM28 and overexpression cell models to assess tumor proliferation, CD8 + T cell co-cultures, flow cytometry, and patient-derived xenograft models. Co-immunoprecipitation and GST pull-down assays were used to analyze the TRIM28-poly (ADP-ribose) polymerase 1 (PARP1) interaction. SUMOylation/ubiquitination studies elucidated the mechanism regulating PARP1 stability, and chromatin immunoprecipitation-quantitative PCR identified the transcriptional regulation of programmed death-ligand 1 (PD-L1). High-throughput screening was conducted with RNA-seq, liquid chromatography–tandem mass spectrometry, and metabolomics. Virtual screening identified the TRIM28 inhibitor Eltrombopag, which was tested in combination with anti-programmed cell death protein-1 (PD-1) therapy for in vivo efficacy and metabolic reprogramming.
Results
We identified TRIM28 as a central regulator of immune evasion in ccRCC. Using high-throughput gene knockout screening, we demonstrated that TRIM28 depletion reprograms malignant epithelial cells toward a less aggressive phenotype and significantly enhances tumor cell susceptibility to cytotoxic T lymphocyte killing. Mechanistically, TRIM28 promotes immune resistance through dual immunometabolic mechanisms: first, by stabilizing PARP1 and promoting its SUMOylation, which in turn amplifies PD-L1 expression via NAD + -SIRT1-p65 signaling; second, by depleting NAD + in the TME, limiting NAD + availability for CD8 + T cells and impairing their respiration and effector function. These findings provide a novel mechanistic framework for TRIM28-driven immune suppression, integrating tumor-intrinsic metabolic reprogramming with CD8 + T cell dysfunction. Notably, we identified Eltrombopag as a candidate TRIM28 inhibitor, which synergized with anti-PD-1 therapy to enhance antitumor immunity and overcome ICB resistance in murine models.
Conclusions
This study reveals that TRIM28 is a key regulator of PD-L1 expression and T cell dysfunction in ccRCC through PARP1 stabilization and NAD + metabolic reprogramming. Targeting TRIM28/PARP1/PDL1 with Eltrombopag reshapes the immunosuppressive TME and enhances checkpoint blockade efficacy, providing a novel combinatorial strategy for ccRCC immunotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Jiangxi Provincial Key Laboratory of Urinary System Diseases, Department of Urology, the First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, China.
- Molecular Medicine of Jiangxi Key Laboratory, the Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, China.
- Department of Urology, Xinhua Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China ndyfy02157@ncu.edu.cn cuixingang@xinhuamed.com.cn ndyfy10021@ncu.edu.cn.
- Jiangxi Provincial Key Laboratory of Urinary System Diseases, Department of Urology, the First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, China ndyfy02157@ncu.edu.cn cuixingang…
Förderung
- Jiangxi Provincial Health Commission Technology Creative Key Project
- Medical Interdisciplinary Innovation Fund of Nanchang University
- Jiangxi Provincial Natural Science Foundation for Distinguished Young Scholars
- National Natural Science Foundation of China
- Jiangxi Provincial Natural Science Foundation
- National Natural Science Foundation of P.R. China
- the National Natural Science Foundation of P.R. China
- Natural Science Foundation of Jiangxi
Zitieren
APA
Zhan, X., Hu, H., Liu, Y., Wan, H., Zheng, F., Chen, L., Liu, X., Xiong, J., Cui, X., Xu, S., & Fu, B. (2025). TRIM28 drives immune evasion via PARP1 SUMOylation and NAD + depletion in clear cell renal cell carcinoma. Journal for ImmunoTherapy of Cancer, 13(10), e013025. https://doi.org/10.1136/jitc-2025-013025
Vancouver
Zhan X, Hu H, Liu Y, Wan H, Zheng F, Chen L, et al. TRIM28 drives immune evasion via PARP1 SUMOylation and NAD + depletion in clear cell renal cell carcinoma. Journal for ImmunoTherapy of Cancer. 2025;13(10):e013025. doi:10.1136/jitc-2025-013025
BibTeX
@article{Zhan2025,
author = {Zhan, Xiangpeng and Hu, Hongji and Liu, Yang and Wan, Hao and Zheng, Fuchun and Chen, Luyao and Liu, Xiaoqiang and Xiong, Jing and Cui, Xingang and Xu, Songhui and Fu, Bin},
title = {TRIM28 drives immune evasion via PARP1 SUMOylation and NAD + depletion in clear cell renal cell carcinoma},
journal = {Journal for ImmunoTherapy of Cancer},
year = {2025},
volume = {13},
number = {10},
pages = {e013025},
doi = {10.1136/jitc-2025-013025}
}
EUVIMED